Results 61 to 70 of about 11,874 (152)

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2162-2170, July 2026.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013

Neurología, 2015
Resumen: Introducción: Natalizumab es un tratamiento que ha demostrado ser muy eficaz en los ensayos clínicos y muy efectivo en la práctica clínica en los pacientes con esclerosis múltiple recurrente-remitente, en cuanto a la reducción del número de ...
O. Fernández, J.A. García-Merino, R. Arroyo, J.C. Álvarez-Cermeño, G. Izquierdo, A. Saiz, J. Olascoaga, A. Rodríguez-Antigüedad, J.M. Prieto, C. Oreja-Guevara, M.A. Hernández, E. Moral, J. Meca, X. Montalbán   +13 more
doaj   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna, Jiezhun Gu, Yi‐Ju Li, Huiman Barnhart, Dina Halegoua‐DeMarzio, Herbert L. Bonkovsky, A. Sidney Barritt, Jean P. Molleston, Naga P. Chalasani, Marwan Ghabril   +9 more
wiley   +1 more source

A Comprehensive Disproportionality Analysis of Drug‐Related Head Injury Reports Using the FAERS Database

Brain and Behavior, Volume 16, Issue 6, June 2026.
ABSTRACT Objective This study aimed to identify and characterize drugs associated with reports of head injury through a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database. Methods A retrospective disproportionality analysis was conducted on FAERS reports from 2004 to 2023.
Jiaqi Guo, Luming Wei, Junfeng Liu, Jimei Zhang, He Wang, Wanjun Lu   +5 more
wiley   +1 more source

When Treatment Turns to Stone: Injection‐Site Calcinosis Associated With Interferon‐β in Multiple Sclerosis: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Injection‐site calcinosis is a rare complication of interferon‐β therapy in multiple sclerosis. We report a 52‐year‐old woman with stable bilateral gluteal calcifications after long‐term subcutaneous interferon‐β‐1b therapy. Findings were most consistent with probable dystrophic calcinosis cutis secondary to chronic repeated injection‐site ...
Anna Walter, Adam Bott, Marianne Kiechle, Margret Hund‐Georgiadis   +3 more
wiley   +1 more source

Review: Natalizumab in the treatment of multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2009
Natalizumab reduced the rate of clinical relapse at one year by 68% and the risk of sustained progression of disability by 42—54% over 2 years in its pivotal phase III trial (AFFIRM) in relapsing—remitting multiple sclerosis (RRMS).
Özgür Yaldizli, Norman Putzki
doaj   +1 more source

Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy (PML).

Frontiers in Neurology, 2013
Natalizumab (Tysabri®) is a monoclonal antibody that prevents inflammatory cells from binding to brain endothelial cells and passing into the brain parenchyma.
Hans eLindå, Anders evon Heijne
doaj   +1 more source

Natalizumab for the treatment of relapsing multiple sclerosis

Biologics: Targets & Therapy, 2008
Richard A Rudick1, Michael A Panzara21Cleveland Clinic Foundation, Cleveland, OH, USA; 2Biogen Idec, Inc., Cambridge, MA, USAAbstract: Natalizumab is an α4-integrin antagonist approved as monotherapy for patients with relapsing multiple ...
Richard A Rudick, Michael A Panzara
doaj  

A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab

Multiple Sclerosis Journal - Experimental, Translational and Clinical
Background Fatigue is the most debilitating symptom in patients with multiple sclerosis (MS). Natalizumab and rituximab are the most used MS disease modifying therapies in Sweden, but comparative data on the effect on fatigue is sparse. Objective Primary
Johan Hellgren, Maria Compagno Strandberg, Kristina Källén, Anders Svenningsson   +3 more
doaj   +1 more source

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

PLoS Pathogens, 2012
Progressive multifocal leukoencephalopathy (PML) induced by JC virus (JCV) is a risk for natalizumab-treated multiple sclerosis (MS) patients. Here we characterize the JCV-specific T cell responses in healthy donors and natalizumab-treated MS patients to
Molly R Perkins, Caroline Ryschkewitsch, Julia C Liebner, Maria Chiara G Monaco, Danielle Himelfarb, Sara Ireland, Annelys Roque, Heather L Edward, Peter N Jensen, Gina Remington, Thomas Abraham, Jaspreet Abraham, Benjamin Greenberg, Charles Kaufman, Chris LaGanke, Nancy L Monson, Xiaoning Xu, Elliot Frohman, Eugene O Major, Daniel C Douek   +19 more
doaj   +1 more source